Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, Gayevskiy V, Elhossiny AM, Srivastava MK, Patil NS, Smith KA, Jesudason R, Chan C, Chang PS, Fernandez M, Rost S, McGinnis LM, Koeppen H, Gay CM, Minna JD, Heymach JV, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS. Nabet BY, et al. Among authors: liu sv. Cancer Cell. 2024 Mar 11;42(3):429-443.e4. doi: 10.1016/j.ccell.2024.01.010. Epub 2024 Feb 15. Cancer Cell. 2024. PMID: 38366589
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Among authors: liu sv. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.
Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Watson AS, et al. Among authors: liu sv. Clin Lung Cancer. 2024 Sep 12:S1525-7304(24)00196-7. doi: 10.1016/j.cllc.2024.09.001. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39384504
NRG1 Fusions in NSCLC: Being eNRGy Conscious.
Gupta B, Gosa Barrett L, Liu SV. Gupta B, et al. Among authors: liu sv. Lung Cancer (Auckl). 2024 Oct 3;15:143-148. doi: 10.2147/LCTT.S464626. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 39376790 Free PMC article. Review.
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Neal JW, et al. Among authors: liu sv. JTO Clin Res Rep. 2024 Mar 20;5(10):100666. doi: 10.1016/j.jtocrr.2024.100666. eCollection 2024 Oct. JTO Clin Res Rep. 2024. PMID: 39318387 Free PMC article.
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV. Reck M, et al. Among authors: liu sv. Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10. Lung Cancer. 2024. PMID: 39306923 Clinical Trial.
188 results